Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of pegylated interferon alfa-2b in myeloproliferative neoplasms: A multicenter retrospective study of 210 patients

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDexiao KongSecond Hospital of Shandong UniversityGLGuozhen LiuZoucheng People's HospitalQJQingli JiQilu Hospital of Shandong University

Discussion

Loading...

Member takes

Overview

Retrospective study shows high response rates and manageable adverse events in patients with MPN, indicating safety of Peg-IFN-α-2b.

Key Points

  • To evaluate the efficacy and safety of pegylated interferon alfa-2b in treating myeloproliferative neoplasms.
  • Multicenter retrospective study of 210 MPN patients
  • Evaluation of hematologic overall response rate and molecular response rate
  • Assessment of treatment-emergent adverse events incidence
  • 97.74% overall response rate at 6 months, increasing to 99.12% at 12 months
  • 63.41% molecular response rate among evaluated patients
  • Adverse events occurred in 53.33% of patients, primarily hepatic dysfunction and hematologic toxicity

Cite This Study

Kong et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfd2https://doi.org/10.1182/blood-2025-7336
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis2025 · 1 citations
  2. 2Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry2025
  3. 3Molecular response and outcomes in patients with myeloproliferative neoplasms treated with interferon in the real-world setting.2026 · 1 citations
  4. 4Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study2019 · 108 citations
  5. 5Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patients2024 · 2 citations